Clustering of cardiovascular risk factors: targeting high-risk individuals (Q40440943)

20 September 2017

1 reference

title

Clustering of cardiovascular risk factors: targeting high-risk individuals (English)

1 reference

20 September 2017

1 reference

J Genest

1

1 reference

PubMed ID

7604805

20 September 2017

J S Cohn

series ordinal

2

1 reference

PubMed ID

7604805

20 September 2017

language of work or name

English

0 references

publication date

1 July 1995

1 reference

American Journal of Cardiology

20 September 2017

1 reference

20 September 2017

76

1 reference

20 September 2017

2

1 reference

20 September 2017

8A-20A

1 reference

Probability of Middle-Aged Men Developing Coronary Heart Disease in Five Years

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

The value of lowering cholesterol after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Myocardial perfusion and regression of coronary artery disease in patients on a regimen of intensive physical exercise and low fat diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Design features of a controlled clinical trial to assess the effect of an HMG CoA reductase inhibitor on the progression of coronary artery disease. Canadian Coronary Atherosclerosis Intervention Trial Investigators Montreal, Ottawa, and Toronto, Ca

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Are we mortgaging the medical profession?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

The pathogenesis of coronary artery disease and the acute coronary syndromes (2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Prognostic significance of progression of coronary atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Familial lipoprotein disorders in patients with premature coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Familial lipoprotein disorders and premature coronary artery disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

A receptor-mediated pathway for cholesterol homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Regulation of the mevalonate pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Molecular genetics of the LDL receptor gene in familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Homozygous familial hypercholesterolemia among French Canadians in Québec Province

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Familial defective apolipoprotein B-100. Comparison with familial hypercholesterolemia in 18 cases detected in Munich

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Apolipoprotein E: cholesterol transport protein with expanding role in cell biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

The role of apolipoprotein E genetic variants in lipoprotein disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Inheritance of combined hyperlipoproteinemia: evidence for a new lipoprotein phenotype.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Prevalence of lipoprotein (a) [Lp(a)] excess in coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Familial hypoalphalipoproteinemia in premature coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

DNA polymorphisms of the apolipoprotein B gene in patients with premature coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Analysis of DNA changes in the LPL gene in patients with familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus Relationships with lipids, apolipoproteins, and premature coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Banting lecture 1988. Role of insulin resistance in human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Hyperinsulinemia. A link between hypertension obesity and glucose intolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Prevalence of risk factors in men with premature coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Family history of heart attack as an independent predictor of death due to cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

An updated coronary risk profile. A statement for health professionals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Changes in blood rheology in patients with stable angina pectoris as a result of coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Fibrinogen, factor VII clotting activity and coronary artery disease severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Fibrinogen as a risk factor for stroke and myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Fibrinogen and risk of cardiovascular disease. The Framingham Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

The role of fibrinogen as a cardiovascular risk factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Fibrinogen genotype and risk of peripheral atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Activation of coagulation factor VII during alimentary lipemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Plasma factor VII is activated by postprandial triglyceridaemia, irrespective of dietary fat composition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Platelet hyperreactivity and prognosis in survivors of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Blood platelet count and function are related to total and cardiovascular death in apparently healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Fat tolerance in subjects with atherosclerosis: heparin effects upon lipemia, lipoproteins, and gamma globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Alimentary lipaemia in men with coronary artery disease and in controls.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Alimentary lipaemia and haparin clearing in ischaemic heart-disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Postprandial lipemia, fenofibrate and coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Hypertriglyceridemic Very Low Density Lipoproteins Induce Triglyceride Synthesis and Accumulation in Mouse Peritoneal Macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Very low density lipoproteins stimulate cholesteryl ester formation in U937 macrophages. Heterogeneity and biologic variation among normal humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Cholesterol accumulation in J774 macrophages induced by triglyceride-rich lipoproteins. Comparison of very low density lipoprotein from subjects with type III, IV, and V hyperlipoproteinemias.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Uptake of chylomicron remnants by the native LDL receptor in human monocyte-derived macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Apolipoprotein E is the determinant that mediates the receptor uptake of beta-very low density lipoproteins by mouse macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Lipolytic surface remnants of triglyceride-rich lipoproteins are cytotoxic to macrophages but not in the presence of high density lipoprotein. A possible mechanism of atherogenesis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Lipolyzed hypertriglyceridemic serum and triglyceride-rich lipoprotein cause lipid accumulation in and are cytotoxic to cultured human endothelial cells. High density lipoproteins inhibit this cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Disruption of endothelial barrier function by lipolytic remnants of triglyceride-rich lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Cholesterol and lipoproteins: beyond atherogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Lipolysis of triglyceride-rich lipoproteins activates coagulant factor XII: a study in familial lipoprotein-lipase deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Levels of plasma factor VII and factor VII activated forms as a function of plasma triglyceride levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Investigations into the haemorheological significance of postprandial and fasting hypertriglyceridaemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

[Effect of fenofibrate on fibrinogen concentration and blood viscosity. Consequences for myocardial microcirculation in coronary heart disease?]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Effects of fenofibrate on angiographically examined coronary atherosclerosis and left ventricular function in hypercholesterolemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Progression and regression of minor coronary arterial narrowings by quantitative angiography after fenofibrate therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Direct effects of gemfibrozil on the fibrinolytic system. Diminution of synthesis of plasminogen activator inhibitor type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Gemfibrozil predictably lowers triglycerides but does not significantly change plasminogen activator inhibitor activity in hypertriglyceridemic patients with a history of thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

Plasma triglyceride and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Hyperapobetalipoproteinemia. Plasma lipoprotein responses to oral fat load.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980010-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9149(05)80010-4

1 reference

20 September 2017

1 reference

PubMed ID

7604805